Disseminated intravascular coagulation in sepsis. Export

@article{citeulike:2873516, abstract = {Disseminated intravascular coagulation is a frequent complication of sepsis. Coagulation activation, inhibition of fibrinolysis, and consumption of coagulation inhibitors lead to a procoagulant state resulting in inadequate fibrin removal and fibrin deposition in the microvasculature. As a consequence, microvascular thrombosis contributes to promotion of organ dysfunction. Recently, three randomized, double-blind, placebo-controlled trials investigated the efficacy of antithrombin, activated protein C (APC), and tissue factor pathway inhibitor, respectively, in sepsis patients. A significant reduction in mortality was demonstrated in the APC trial. In this article, we first discuss the physiology of coagulation and fibrinolysis activation. Then, the pathophysiology of coagulation activation, consumption of coagulation inhibitors, and the inhibition of fibrinolysis leading to a procoagulant state are described in more detail. Moreover, therapeutic concepts as well as the three randomized, double-blind, placebo-controlled studies are discussed.}, address = {Central Hematology Laboratory, University Hospital, Berne, Switzerland.}, author = {Zeerleder, S. and Hack, C. E. and Wuillemin, W. A.}, citeulike-article-id = {2873516}, citeulike-linkout-0 = {http://dx.doi.org/10.1378/chest.128.4.2864}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/16236964}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=16236964}, doi = {10.1378/chest.128.4.2864}, issn = {0012-3692}, journal = {Chest}, keywords = {10, 13, coagulopathy, dic, sepsis}, month = {October}, number = {4}, pages = {2864--2875}, posted-at = {2008-06-08 15:08:38}, priority = {2}, title = {Disseminated intravascular coagulation in sepsis.}, url = {http://dx.doi.org/10.1378/chest.128.4.2864}, volume = {128}, year = {2005} }

TY - JOUR ID - citeulike:2873516 L3 - citeulike-article-id:2873516 N2 - Disseminated intravascular coagulation is a frequent complication of sepsis. Coagulation activation, inhibition of fibrinolysis, and consumption of coagulation inhibitors lead to a procoagulant state resulting in inadequate fibrin removal and fibrin deposition in the microvasculature. As a consequence, microvascular thrombosis contributes to promotion of organ dysfunction. Recently, three randomized, double-blind, placebo-controlled trials investigated the efficacy of antithrombin, activated protein C (APC), and tissue factor pathway inhibitor, respectively, in sepsis patients. A significant reduction in mortality was demonstrated in the APC trial. In this article, we first discuss the physiology of coagulation and fibrinolysis activation. Then, the pathophysiology of coagulation activation, consumption of coagulation inhibitors, and the inhibition of fibrinolysis leading to a procoagulant state are described in more detail. Moreover, therapeutic concepts as well as the three randomized, double-blind, placebo-controlled studies are discussed. IS - 4 JF - Chest SN - 0012-3692 AD - Central Hematology Laboratory, University Hospital, Berne, Switzerland. EP - 2875 TI - Disseminated intravascular coagulation in sepsis. VL - 128 SP - 2864 KW - 10 KW - 13 KW - coagulopathy KW - dic KW - sepsis AU - Zeerleder, S AU - Hack, CE AU - Wuillemin, WA PY - 2005/10// UR - http://dx.doi.org/10.1378/chest.128.4.2864 ER -